Results 131 to 140 of about 5,801 (166)

Immunosuppressants/molnupiravir

Reactions Weekly, 2023
openaire   +2 more sources

Molnupiravir: evidence by press release

Drug and Therapeutics Bulletin, 2021
James A Cave, David Phizackerley
openaire   +2 more sources

A tale of two drugs: Molnupiravir and Paxlovid

Mutation Research - Reviews in Mutation Research
The orally administered antiviral drug Lagevrio or molnupiravir (MOV) and the combination antiviral drug nirmatrelvir/ritonavir or Paxlovid (PAX) have been shown to reduce the likelihood of hospitalization and death for high-risk patients with COVID-19.
Michael D. Waters, Stafford G. Warren
openaire   +2 more sources

Molnupiravir/nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +4 more sources

Molnupiravir

Reactions Weekly
  +4 more sources

Molnupiravir in COVID-19: A systematic review of literature

Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021
Anoop Misra, Awadhesh Singh, Ritu Singh   +2 more
exaly  

Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis

Annals of Medicine, 2022
Mingwei W, Feng Zhanhui, Yongran Cheng   +2 more
exaly  

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

EBioMedicine, 2021
Lana Langendries, Judith Breuer, Xin Zhang   +2 more
exaly  

Green adherent spectrophotometric determination of molnupiravir based on computational calculations; application to a recently FDA-approved pharmaceutical dosage form

Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2023
Sherif Ramzy, Ahmed Hussien, Mohammed Abourehab   +2 more
exaly  

Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis

Clinical Infectious Diseases, 2023
, Ronza Najjar Debbiny, Saliba Walid
exaly